Shares of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) were down 2.3% during mid-day trading on Tuesday . The company traded as low as $30.14 and last traded at $30.52, with a volume of 166,320 shares. The stock had previously closed at $31.24.

A number of analysts recently issued reports on ALDR shares. Zacks Investment Research raised shares of Alder BioPharmaceuticals from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a report on Wednesday, July 20th. Brean Capital started coverage on shares of Alder BioPharmaceuticals in a research report on Wednesday, April 20th. They set a “buy” rating and a $45.00 price objective for the company. Jefferies Group restated a “buy” rating on shares of Alder BioPharmaceuticals in a research report on Thursday, June 30th. Finally, Wells Fargo & Co. started coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, April 21st. They set an “outperform” rating for the company. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $44.00.

The firm has a 50-day moving average price of $28.36 and a 200-day moving average price of $25.49. The company’s market capitalization is $1.52 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings data on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by $0.04. The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $1.14 million. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. The company’s quarterly revenue was up 112900.0% compared to the same quarter last year. On average, equities analysts predict that Alder BioPharmaceuticals Inc. will post ($2.76) EPS for the current fiscal year.

In other news, VP Jeffrey T. L. Smith sold 3,000 shares of Alder BioPharmaceuticals stock in a transaction on Monday, August 15th. The shares were sold at an average price of $31.17, for a total value of $93,510.00. Following the transaction, the vice president now directly owns 3,000 shares of the company’s stock, valued at approximately $93,510. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Randall C. Schatzman sold 10,000 shares of Alder BioPharmaceuticals stock in a transaction on Tuesday, May 24th. The shares were sold at an average price of $28.02, for a total transaction of $280,200.00. Following the completion of the transaction, the chief executive officer now directly owns 115,933 shares in the company, valued at $3,248,442.66. The disclosure for this sale can be found here.

Several institutional investors have made changes to their positions in the stock. Nationwide Fund Advisors boosted its position in shares of Alder BioPharmaceuticals by 103.6% in the fourth quarter. Nationwide Fund Advisors now owns 30,380 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 15,457 shares during the last quarter. California Public Employees Retirement System boosted its position in shares of Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock worth $2,685,000 after buying an additional 72,600 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock worth $8,911,000 after buying an additional 200,707 shares during the last quarter.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.